{"title":"Ombitasvir、paritaprevir和Ritonavir联合利巴韦林治疗上埃及晚期肾病患者慢性丙型肝炎病毒的安全性和有效性","authors":"H. Mahmoud, M. Alemam, Z. Ahmed, H. Osman","doi":"10.21608/svuijm.2022.149784.1340","DOIUrl":null,"url":null,"abstract":"Background: Formerly, treating hepatitis C virus (HCV) infection in individuals suffering from chronic renal disease was challenging due to the toxicity of interferon (IFN). Ombitasvir, paritaprevir, and ritonavir are examples of safe and effective pan-genotypic direct-acting antiviral (DAA) regimens that make it easier for individuals with chronic kidney disease to treat their hepatitis C virus (HCV). Objectives: To assess the effectiveness and safety of Omibtasvir, paritaprevir, and ritonavir when used in conjunction with Ribavirin for the treatment of hepatitis C patients who have end-stage kidney disease. Patients and methods: 100 individuals with severe renal illnesses and chronic hepatitis C virus were included in this cross-sectional investigation. The estimated glomerular filtration rate (eGFR) was calculated after each patient underwent a thorough medical history, physical examination, and laboratory testing that included a complete blood count, ALT, AST, and kidney function tests. Fibroscan and pelvic abdominal ultrasonography were carried out. The patients received ribavirin together with paritaprevir/ritonavir and ombitasvir (75/50/12.5mg) twice day for 12 weeks. Results : Sustained virologic response (SVR) was 83 % (83 patients) overall patients. Patients were divided into two groups according to sustained virologic response. Child Pugh-turcotte (CPT) score was higher in non responders when compared with responders (5.7 ± 0.4 vs 5.4 ± 0.4; P-value = 0.002). Regarding to Safety and tolerability of DAAs, no severe adverse events were reported during the present study with no discontinuing treatment due to adverse events. The most frequent adverse events were anemia, headache, pruritus, anorexia and malaise. Conclusion : OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD with high virologic response and highly safety profile.","PeriodicalId":34789,"journal":{"name":"SVU International Journal of Medical Sciences","volume":"os-48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Efficacy of Ombitasvir, Paritaprevirand Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Virus in Advanced Kidney Diseases Patients in Upper Egypt\",\"authors\":\"H. Mahmoud, M. Alemam, Z. Ahmed, H. Osman\",\"doi\":\"10.21608/svuijm.2022.149784.1340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Formerly, treating hepatitis C virus (HCV) infection in individuals suffering from chronic renal disease was challenging due to the toxicity of interferon (IFN). Ombitasvir, paritaprevir, and ritonavir are examples of safe and effective pan-genotypic direct-acting antiviral (DAA) regimens that make it easier for individuals with chronic kidney disease to treat their hepatitis C virus (HCV). Objectives: To assess the effectiveness and safety of Omibtasvir, paritaprevir, and ritonavir when used in conjunction with Ribavirin for the treatment of hepatitis C patients who have end-stage kidney disease. Patients and methods: 100 individuals with severe renal illnesses and chronic hepatitis C virus were included in this cross-sectional investigation. The estimated glomerular filtration rate (eGFR) was calculated after each patient underwent a thorough medical history, physical examination, and laboratory testing that included a complete blood count, ALT, AST, and kidney function tests. Fibroscan and pelvic abdominal ultrasonography were carried out. The patients received ribavirin together with paritaprevir/ritonavir and ombitasvir (75/50/12.5mg) twice day for 12 weeks. Results : Sustained virologic response (SVR) was 83 % (83 patients) overall patients. Patients were divided into two groups according to sustained virologic response. Child Pugh-turcotte (CPT) score was higher in non responders when compared with responders (5.7 ± 0.4 vs 5.4 ± 0.4; P-value = 0.002). Regarding to Safety and tolerability of DAAs, no severe adverse events were reported during the present study with no discontinuing treatment due to adverse events. The most frequent adverse events were anemia, headache, pruritus, anorexia and malaise. Conclusion : OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD with high virologic response and highly safety profile.\",\"PeriodicalId\":34789,\"journal\":{\"name\":\"SVU International Journal of Medical Sciences\",\"volume\":\"os-48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SVU International Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/svuijm.2022.149784.1340\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SVU International Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/svuijm.2022.149784.1340","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:以前，由于干扰素(IFN)的毒性，治疗慢性肾脏疾病患者的丙型肝炎病毒(HCV)感染具有挑战性。Ombitasvir, paritaprevir和ritonavir是安全有效的泛基因型直接作用抗病毒(DAA)方案的例子，使慢性肾脏疾病患者更容易治疗丙型肝炎病毒(HCV)。目的:评估Omibtasvir、paritaprevir和ritonavir联合利巴韦林治疗终末期肾病的丙型肝炎患者的有效性和安全性。患者和方法:本横断面调查纳入了100例患有严重肾脏疾病和慢性丙型肝炎病毒的患者。估计的肾小球滤过率(eGFR)是在每位患者经过全面的病史、体格检查和实验室检查(包括全血细胞计数、ALT、AST和肾功能检查)后计算出来的。进行纤维扫描和盆腔腹部超声检查。利巴韦林联合paritaprevir/ritonavir和ombitasvir (75/50/12.5mg)治疗12周，每日2次。结果:83例患者的持续病毒学应答(SVR)为83%。根据持续病毒学反应情况将患者分为两组。无应答者的儿童Pugh-turcotte (CPT)评分高于应答者(5.7±0.4 vs 5.4±0.4;p值= 0.002)。关于DAAs的安全性和耐受性，在本研究中没有报道严重的不良事件，也没有因不良事件而停止治疗。最常见的不良事件是贫血、头痛、瘙痒、厌食和不适。结论:OBV/PTV/RTV联合利巴韦林治疗慢性HCV合并ESRD患者具有高病毒学应答和高安全性。
Safety and Efficacy of Ombitasvir, Paritaprevirand Ritonavir Combination with Ribavirin for Treatment of Chronic Hepatitis C Virus in Advanced Kidney Diseases Patients in Upper Egypt
Background: Formerly, treating hepatitis C virus (HCV) infection in individuals suffering from chronic renal disease was challenging due to the toxicity of interferon (IFN). Ombitasvir, paritaprevir, and ritonavir are examples of safe and effective pan-genotypic direct-acting antiviral (DAA) regimens that make it easier for individuals with chronic kidney disease to treat their hepatitis C virus (HCV). Objectives: To assess the effectiveness and safety of Omibtasvir, paritaprevir, and ritonavir when used in conjunction with Ribavirin for the treatment of hepatitis C patients who have end-stage kidney disease. Patients and methods: 100 individuals with severe renal illnesses and chronic hepatitis C virus were included in this cross-sectional investigation. The estimated glomerular filtration rate (eGFR) was calculated after each patient underwent a thorough medical history, physical examination, and laboratory testing that included a complete blood count, ALT, AST, and kidney function tests. Fibroscan and pelvic abdominal ultrasonography were carried out. The patients received ribavirin together with paritaprevir/ritonavir and ombitasvir (75/50/12.5mg) twice day for 12 weeks. Results : Sustained virologic response (SVR) was 83 % (83 patients) overall patients. Patients were divided into two groups according to sustained virologic response. Child Pugh-turcotte (CPT) score was higher in non responders when compared with responders (5.7 ± 0.4 vs 5.4 ± 0.4; P-value = 0.002). Regarding to Safety and tolerability of DAAs, no severe adverse events were reported during the present study with no discontinuing treatment due to adverse events. The most frequent adverse events were anemia, headache, pruritus, anorexia and malaise. Conclusion : OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD with high virologic response and highly safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
